Home | Back to newsletter main page
| |
 |
|
February 18, 2013 |
|
CASE CCC IN THE NEWSCleveland Clinic Develops Clinical Screening Program for Top Genetic Cause of Colon Cancer Discovery in HIV May Solve Efficiency Problems for Gene Therapy Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme Vaccine With Drug Payload Shows Promise Against Tumors ANNOUNCEMENTSSummer Volunteers: Placements NeededIt's that time of year again where we receive requests from students inquiring about summer research positions. If you have room in your lab for a summer student, please send an email to Lyn Haselton, Cancer Center Training Program Manager. We will add your name to a list and will send you resumes if we receive them. Case CCC Funding for Pilot/Phase I Clinical TrialsThe Case CCC is encouraging investigators to submit Letters of Intent for Early Phase Clinical Research Support (EPCRS; former Protocol Specific Research Support) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Revised NCI Cancer Center Support Grant EPCRS guidelines are effective as of April 1, 2013. Studies developed jointly between UH and Cleveland Clinic with planned accrual at both institutions will be given higher priority. There are no specific deadlines for submission, and applications will be accepted until all funds are committed. Please direct questions and requests for information about the revised guidelines and funding process to Katarzyna Karelus, Clinical Research Office Administrative Director, kxk384@case.edu, 216.844.4176. Tissue Microarray SurveyThe Cancer Center is considering an initiative to build a series of Tissue Microarrays (TMAs) for member usage. We would like to assess the needs of our members so that we can start with the most feasible and useful TMAs. Please take this short survey regarding your research goals and needs. Database Systems Development SurveyThe Cancer Center is considering a more standardized and integrated database system to assist members in collection of clinical and research datasets. This new system would allow for the integration of many types of data that are commonly used in research studies, such as (but not limited to) biological samples, data from the clinical record, outcomes, pathology, survey, demographics and "omics" data results. We recognize that we do not have optimal systems currently in place. To help us assist you in your research needs regarding your data collection and data management needs over the next 2 to 5 years, we have developed a short questionnaire. We cannot entertain this investment without considerable use by Cancer Center members. Your responses will help us make a strategic decision on database systems development. Reminder: Registration of Studies in Clinicaltrials.gov and Reporting of Clinical Trial ResultsSection 801 of the Food and Drug Administration Amendments Act (FDAAA 801) requires Responsible Parties to register and submit summary results of clinical trials with Clinicaltrials.gov. Clinical trial results registration became effective as of September 2008. The FDA is currently empowered to enforce the reporting requirements, as well as financial penalties on non-compliant investigators and institutions. Clinical trial and result registration is centralized within the Case CCC, and April Firstencel, Case CCC Registration Coordinator, has been working with investigators, study staff and statisticians to ensure the Case CCC complies with federal requirements. This announcement serves as a reminder about our on-going efforts and the need for everybody's assistance and collaboration to meet these obligations. Please direct questions to April Firstencel, Case CCC Registration Coordinator for Clinicaltrials.gov, 216.286.2294, april.firstencel@case.edu. FUNDING OPPORTUNITIES/AWARDSASH-AMFDP AwardThe American Society of Hematology (ASH) has partnered with the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation to increase the number of scholars from historically disadvantaged backgrounds receiving academic and research appointments in the field of hematology. The AMFDP offers four-year postdoctoral research awards to historically disadvantaged physicians who are committed to developing careers in academic medicine and to serving as role models for students and faculty of similar backgrounds. The program defines "historically disadvantaged" individuals as those who face challenges because of their race, ethnicity, socioeconomic status, or other similar factors. Deadline: March 14 Computational Genomic Epidemiology of Cancer Postdoctoral Training ProgramThe Case CCC invites applications to its 2-3 year NCI-funded Computational Genomic Epidemiology of Cancer Postdoctoral Training Program. The program combines a mentored cancer research project designed by the fellow in collaboration with their mentors with a specialized curriculum of formal didactic training and individualized longitudinal curriculum. This program is designed to prepare trainees for careers as independent investigators engaged in research at the intersection of cancer research, genetics, epidemiology, biostatistics and computer science. Cancer researchers obtaining training will have the skills vital to decipher the complex pathways comprising genetic and environmental risk factors for disease, and will ultimately be able to provide clinicians and their patients with valuable information for the prevention and treatment of cancer. Candidates with an MD, PhD, or MD/PhD degree, strong quantitative skills, and an interest in a career in genetics research are encouraged to apply. MARK YOUR CALENDARSResearch Best Practices Day 2013Registration is now open for Research Best Practices Day 2013, Friday, March 1. This annual event is open to the entire research community. Each year, several topics are presented by our local experts as part of CWRU's ongoing training in the Responsible Conduct of Research. Faculty, staff and students are encouraged to attend one or more of the sessions that are applicable to their research. Planned topics include:
Breast Cancer Program in Development Annual RetreatDrs. William Schiemann and Lyndsay Harris, Co-Leaders of the Breast Cancer Program in Development, invite you to attend the program Annual Retreat on Monday, March 11 from 9 am-3 pm in the Dively Building on CWRU campus. The agenda and program information will be available soon. Melanoma Mini-SymposiumA melanoma mini-symposium is scheduled from 3-7 pm on Monday, March 11 in the Wolstein Research Building Auditorium. The purpose of this symposium is to provide a forum for physician scientists and biomedical researchers to foster communication and develop new collaborations on melanoma research. Please watch the newsletter for updates. Annual Cancer Center RetreatThe Annual Cancer Center Scientific Retreat will commence the evening of Thursday, July 11 and continue through Friday, July 12. Location and agenda are still be finalized. Details will be posted in the newsletter in the coming months. | EVENTS
February 18Immunology Seminar Series February 19Medicine Grand Rounds February 20Hematology and Oncology Division Research Conference Immunology Invited Speaker Seminar Series February 21Molecular Genetics Seminar Cancer Trainee Seminar Stem Cell Biology and Regenerative Medicine February 22Cancer Center Research in Progress canceled Hematology/Oncology Fellows Conference/Curriculum Series Taussig Cancer Institute Grand Rounds Cancer Center Seminar Series
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTSBreast Cancer Program in Development Annual Retreat Melanoma Mini-Symposium IMPACT: Improving Sickle Cell Patient Adherence Through Collaborative Teaching Breast Cancer Conference Annual Cancer Center Scientific Retreat
ADDITIONAL UPCOMING SEMINARS & EVENTS16th Annual Meeting of the Translational Research Cancer Centers Consortium (TRC3): The Power of Negative Thinking: Inhibiting the Inhibitors of Tumor Immunity National GvHD Health Symposium |
|
|
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES |
|
|
Case CCC ACS IRG |
Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC) |
|
|
|
NIH BULLETIN – Notices and Funding Opportunities |
|
| Produced by: Gillian Irwin Todd 11100 Euclid Avenue, Wearn 149 Cleveland, Ohio 44106-5065 216.844.8317 phone 216.844.7832 fax gillian.irwin@case.edu |
HELP US HELP YOU!If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to gillian.irwin@case.edu. |
|
|